Table 3– Mean values and change at 12 and 24 months for secondary outcomes

	12 months						24 months
	Doxycycline		Placebo		*Difference for change doxycycline versus* placebo**	p-value	Doxycycline		Placebo		*Difference for change doxycycline versus* placebo**	p-value^#
	Mean	Change	Mean	Change	*Difference for change doxycycline versus* placebo**	p-value	Mean	Change	Mean	Change	*Difference for change doxycycline versus* placebo**	p-value^#
Patients completing	9		8				8		7
FVC L	3.09±0.78	0.19±0.10	3.04±0.68	0.05±0.11	0.15 (-0.26– -0.03)	0.008	3.05±0.83	0.05±0.18	3.09±0.74	0.004±0.11	−0.05 (-0.22–0.12)	0.24
T_LCO mmol·kPa⁻¹·min⁻¹	3.83±1.98	-0.02±0.27	4.91±1.87	0.16±0.33	0.18 (-0.11–0.48)	0.11	4.23±2.00	-0.04±0.56	5.31±1.47	0.08±0.48	0.11 (-0.47–0.69)	0.33
Shuttle walk distance m	617±338	33±145	554±369	-13 ±139	-46 (-189–97)	0.25	632±340	4±174	630±232	-1±188	-5.18(-207–197)	0.48
SGRQ
Symptoms	42.2±30	-0.8±16.9	32.5±21.7	0.48±8.6	-1.24 (-15.3–12.8)	0.43	37.4±20.4	5.0±14.7	35.4±25.4	-7.1±19.3	12.1 (-7.9–32.0)	0.11
Activity	50.8±32.3	-1.7±7.5	51.2±26.1	4.7±9.7	-5.8 (-14.5–2.8)	0.08	48.3±25.9	0.78±12.2	51.1±22.5	7.1±8.2	-6.3 (-18.5–5.9)	0.14
Impact	30.2±24.9	-3.7±11.8	25.1±18.9	-2.8±7.3	-0.75 (-10.6–9.1)	0.44	26.5 ±18.0	2.1±4.9	22.7±11.8	0.7±5.7	1.2 (-4.5–6.9)	0.33
Total score	40.2±27.6	-3.1±9.8	32.0±20.7	-0.05±4.9	-3.0 (-11.4–5.3)	0.22	32.2 ±21.4	1.7±6.9	31.4±16.6	1.3±4.6	0.42 (-6.4–7.2)	0.45
VEGF-D pg·mL⁻¹	2135±1256	-107±246	2751±1387	-69±981	38 (-680–756)	0.91	2229 ±1083	-412±562	2660±1427	-290±849	122 (776–1019)	0.77

Data are presented as n, mean±sd or mean (95% CI), unless otherwise stated. FVC: forced vital capacity; T_LCO: transfer factor of the lung for carbon monoxide; SGRQ: St George’s Respiratory Questionnaire; VEGF-D: vascular endothelial growth factor. ^#: p-values are for the difference between the changes for doxycycline and placebo at the two time-points.